I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update
GAITHERSBURG, MD. and SHANGHAI, China – March 20, 2023 –I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.
I-Mab Conference Call Information
Investors and analysts are invited to join the conference call at 8:15 a.m. EST on March 31 via Zoom:
Meeting ID: 852 0704 2705